2021
DOI: 10.1007/s00262-021-03014-2
|View full text |Cite
|
Sign up to set email alerts
|

Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
12
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
6

Relationship

3
3

Authors

Journals

citations
Cited by 6 publications
(15 citation statements)
references
References 39 publications
2
12
1
Order By: Relevance
“…Three types of patient samples (n = 215) were analyzed: treatment-naïve patients (n = 144), patients on treatment (OT) with ibrutinib (n = 52), and ibrutinib relapsed/refractory patients (n = 19). The characteristics of samples used in this study have been disclosed before [ 22 ].…”
Section: Methodsmentioning
confidence: 99%
See 2 more Smart Citations
“…Three types of patient samples (n = 215) were analyzed: treatment-naïve patients (n = 144), patients on treatment (OT) with ibrutinib (n = 52), and ibrutinib relapsed/refractory patients (n = 19). The characteristics of samples used in this study have been disclosed before [ 22 ].…”
Section: Methodsmentioning
confidence: 99%
“…Analysis of CCR7 expression was conducted, according to published protocols [ 22 ], in whole PB samples with a four-color panel of fluorochrome-labelled monoclonal antibody (mAb): CD19-APC/H7 (SJ25C1), CD3-FITC (SK7) and CD5-APC (L17F12) from BD Biosciences (San Jose, CA, USA), and CCR7-PE (clone 150503) from R&D Systems (Minneapolis, MN). A corresponding PE-conjugated isotype control (IC) was included (R&D Systems).…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…Moreover, Catapult Therapeutics presented first pre-clinical results of an antagonist mAb called CAP-100 that will be evaluated in first-inhuman clinical trials in 2021 (NCT04704323) (244). In preclinical settings, both compounds have shown to be highly effective as a single agent and at least CAP-100 revealed the potential for combinations with current standard-of-care drugs (245). Owing to their particular MOA, antagonisticanti-CCR7 mAbs may be likely combined with other standard-of-care drugs to obtain additive or synergistic effects while reducing the likelihood of treatment resistances.…”
Section: Ccr7 As a Therapeutic Target In Blood Cancersmentioning
confidence: 99%
“…Along with the BTK inhibitor ibrutinib or with the PI3Kd inhibitor idelalisib, anti-CCR7 mAbs would additively or synergistically target CCR7-mediated adhesion to lymphoid stroma or endothelium, thus favoring an enhanced cell egress from lymphoid tissues into circulation (44,46,48,246). In fact, we have recently demonstrated that CCR7 expression and functionality is not impaired during ibrutinib treatment in CLL patients and that the anti-CCR7 CAP-100 and ibrutinib show complementary activities (245). Moreover, while the antibody would block recirculation and loops of LN homing, ibrutinib would also interfere with CXCR4-and CXCR5mediated signaling and with the production of chemokines (CXCL12, CXCL13, CCL19) by myeloid stroma cells (44,247), thus acting against potential redundant chemotactic pathways.…”
Section: Ccr7 As a Therapeutic Target In Blood Cancersmentioning
confidence: 99%